MyFinsight
Home
Blog
About
Contact
Download
Download image
Net change in cash
and restricted cash
-$5,518,107
Net income (loss)
$18,593,806
Accounts payable
$3,097,484
Deferred tax expense
$1,478,813
Depreciation and
amortization
$268,662
Provision for losses on
accounts receivable
$134,267
Amortization of finance
leases - right-of-use...
$119,473
Amortization of operating
leases - right-of-use...
$119,100
Non-cash compensation
through the issuance of...
$45,096
Amortization of debt discount
- bonds offering...
$3,545
Proceeds from exercise of
stock options
$90,213
Net cash provided by
operating activities
-$5,278,400
Net cash used in
investing activities
-$206,072
Net cash used in
financing activities
-$33,635
Canceled cashflow
$23,860,246
Canceled cashflow
$90,213
Change in fair value of
derivative financial...
$11,817,375
Purchase of property and
equipment
$206,072
Payments on principal on
finance lease...
$96,594
Accounts receivable
$7,791,917
Inventory
$6,934,201
Prepaid expenses and
other current assets
$1,926,764
Accrued expenses
-$604,521
Lease obligations -
operating leases
-$119,573
Loan payments
$27,254
Back
Back
Cash Flow
source: myfinsight.com
ELITE PHARMACEUTICALS INC NV (ELTP)
ELITE PHARMACEUTICALS INC NV (ELTP)